Physician profile
David R Schifter
NPI 1174553937
$7,579.33
in general payments reported to CMS, 2019-2025
26 companies · $1,047 in 2025
The $1,047 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,827 · 2020: $428 · 2021: $1,272 · 2022: $1,577 · 2023: $779 · 2024: $650 · 2025: $1,047.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,465 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,465.42 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,150.85 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $800.40 | 2021-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $718.42 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $659.18 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $649.89 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $571.47 | 2019-2025 | Farxiga, Airsupra |
| E.R. Squibb & Sons, L.L.C. | $536.32 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $504.00 | 2019-2024 | |
| Cvrx, INC. | $474.00 | 2021-2023 | Barostim Neo System |
| Amgen INC. | $264.04 | 2019-2022 | |
| Amarin Pharma, INC. | $203.37 | 2019-2021 | |
| Bardy Diagnostics, INC. | $190.10 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $182.88 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $99.11 | 2020-2024 | Lifevest |
| Kowa Pharmaceuticals America, INC. | $97.83 | 2020-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.07 | 2019-2021 | |
| Abbott Laboratories | $77.47 | 2020-2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Vifor Pharma, INC. | $71.36 | 2021 | |
| Esperion Therapeutics, INC. | $44.94 | 2021 | |
| Kestra Medical Technology Services, INC. | $38.60 | 2022-2023 | Assure Wcd |
| Scpharmaceuticals INC. | $30.86 | 2025 | |
| Boston Scientific Corporation | $26.68 | 2024 | Watchman Flx |
| Alnylam Pharmaceuticals INC. | $25.89 | 2023 | Amvuttra |
| Abiomed | $24.52 | 2023 | Impella |
| Kiniksa Pharmaceuticals, LTD. | $23.37 | 2023 | Arcalyst |
| Biotronik INC. | $17.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Schifter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.